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Background. Choice of adiposity measure may be important in the evaluation of relationships between adiposity and risk markers
for cardiovascular disease and diabetes. Aim. We explored the strengths of risk marker associations with BMI, a simple measure of
adiposity, andwithmeasures provided by skinfold thicknesses and dual energy X-ray absorptiometry (DXA). Subjects andMethods.
We evaluated in three subgroups of white males (𝑛 = 156–349), participating in a health screening program, the strengths of
relationship between measures of total and regional adiposity and risk markers relating to blood pressure, lipids and lipoproteins,
insulin sensitivity, and subclinical inflammation. Results. Independent of age, smoking, alcohol intake, and exercise, the strongest
correlations with adiposity measures were seen with serum triglyceride concentrations and indices of insulin sensitivity, with
strengths of association showing little difference between BMI and skinfold and DXA measures of total and percent body fat
(𝑅 = 0.20–0.46, 𝑃 < 0.01). Significant but weaker associations with adiposity were seen for serum HDL cholesterol and only
relatively inconsistent associationswith adiposity for total andLDL cholesterol and indices of subclinical inflammation.Conclusions.
BMI can account for variation in riskmarkers inwhitemales as well asmore sophisticatedmeasures derived from skinfold thickness
measurements or DXA scanning.
1. Introduction
The relationships between obesity and cardiovascular disease
(CVD) and type 2 diabetes mellitus (T2DM) are currently
understood in terms of systemic changes that excess adipose
tissue can induce in the physiologic andmetabolic risk mark-
ers for these diseases. Adipose tissue products are involved in
the pathogenesis of essential hypertension [1]; moreover, as
an endocrine organ, through its release of various adipokines,
adipose tissue can influence the transport and metabolism of
lipids and lipoproteins [2, 3], glucosemetabolism, and insulin
sensitivity [4, 5] and can promote subclinical inflammation
[6]. Variation in regional adipose tissue distribution may
significantly affect risk markers for T2DM and CVD and
risk of these diseases, with stronger associations for central
obesity than for generalised obesity [7–12].
Elucidation of relationships between adiposity and phys-
iologic and metabolic variables is important for our under-
standing of the role of increasing adiposity in health and
disease, and evaluation of relationships between adiposity
and risk markers is an important aspect of CVD and
T2DM risk evaluation. Choice of adiposity measure is
clearly a consideration in such investigations, and this can
be informed by knowledge of the strength of relationship
between a given adiposity measure and established CVD and
T2DM risk markers. Therefore, it is important to establish
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whether simpler measures of adiposity can provide as much
information as measures that are more complex and more
theoretically rigorous. Here, we test the hypothesis that,
in a cohort restricted to white males, body mass index
(BMI), a frequently used, simple measure of net adiposity,
will correlate with risk markers relating to blood pressure,
lipid and lipoprotein metabolism, insulin sensitivity, and
subclinical inflammation as strongly as more sophisticated
measures. These include a measure of body fat mass derived
from four skinfold thickness measures and direct measures
of total and regional fat mass derived using dual energy X-
ray absorptiometry (DXA).
2. Subjects and Methods
2.1. Design. The Heart Disease and Diabetes Risk Indicators
in a Screened Cohort (HDDRISC) study is an open cohort
study of 1192 white males recruited as part of a company
health screening program. The study began in 1971 and
data collection ended in 2000. Skinfold thicknesses were
measured from the beginning of the study to 1996 and DXA
body fat masses from 1989 to the end of the study. The
majority of those who had skinfolds measured underwent an
oral glucose tolerance test (OGTT) and aminority underwent
an intravenous glucose tolerance test (IVGTT). Among those
who had DXA measurements of body fat mass, very few
underwent anOGTT, but themajority underwent an IVGTT.
Thepresent analysis concerns three bodies of data derived
from the HDDRISC study. Each dataset included partici-
pants who were nondiabetic (fasting plasma glucose, FPG,
<7.0mmol/L) and not grossly obese (BMI < 35.0Kg⋅m−2,
corresponding to 3SD above the mean for baseline BMI
measurements in the entire cohort) and received mea-
surements of BMI, blood pressure, fasting serum total,
low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) cholesterol, triglycerides, fasting plasma glucose and
insulin, and laboratory measures related to inflammation.
Datasets were then distinguished as follows: (1) the 349
men who received measurement of skinfold thicknesses and
assessment of insulin sensitivity by OGTT (“BMI/SF group”
studied between 1972 and 1991); (2) the 269menwho received
measurement of DXA fat masses and assessment of insulin
sensitivity by IVGTT (“BMI/DXA group” studied between
1989 and 1997); (3) the 156 men who received measurement
of both skinfold thicknesses and DXA fat masses and assess-
ment of insulin sensitivity by IVGTT (“BMI/SF/DXA group”
studied between 1989 and 1996).
2.2. Participants. The majority of participants in the
HDDRISC study group were senior executives of a large
company.They were generally healthy and in employment or
recently retired. The study received local ethics committee
approval, and each participant gave their written informed
consent.
2.3. Procedures. All participants fasted overnight (onlywater)
and refrained from smoking and alcohol prior to attending
a dedicated metabolic ward. Here, a full medical history was
taken, including details of smoking habits, alcohol intake, and
exercise behaviour.
Weight and height were measured in light clothing with-
out shoes. Among those receiving skinfold measurements,
skinfold thicknesses were thenmeasured using the procedure
of Durnin and Womersley [13]. Briefly, three measurements
were taken, using Harpenden callipers, at biceps, triceps,
iliac, and subscapular sites. All readings were measured to
the nearest mm, unless values were particularly low (≤5mm)
in which case the nearest 0.5mm was recorded. Among
those undergoingmeasurement of total and regional body fat
tissue by DXA, scans were carried out on a Lunar Radiation
Corporation (Madison, WI, USA) DPX scanner [14] with
total body scanning carried out at a transverse speed of
16 cm/s or 8 cm/s in men who weighed >90 kg, with subjects
receiving radiation doses of 0.05 or 0.1𝜇Gy, respectively [15].
Neither waist nor hip circumferences were measured during
this study.
After 15-minute rest, systolic and diastolic blood pres-
sures (BP) were taken using a mercury sphygmomanometer.
Then, with participants in a semirecumbent position, an
indwelling cannula was inserted in the antecubital vein of
the nondominant arm for blood sampling. Blood samples
were taken for routine haematology and clinical biochemistry
measurements, including white blood cell count (WBC),
erythrocyte sedimentation rate (ESR), serum globulin and
albumin concentrations, serum lipid and lipoprotein con-
centrations (cholesterol, triglycerides, and HDL cholesterol),
and plasma glucose and insulin concentrations (FPG and
FPI, resp.). A second sample for FPG and FPI concentration
measurements was then taken five minutes later. Either an
OGTT or IVGTT was then carried out. For the OGTT, a
glucose load of 1 g/kg body weight was given, with plasma
glucose and insulin measured at 30, 60, 90, 120, 150, and 180
minutes, following consumption of the glucose solution. For
the IVGTT, as previously described [16], a second cannula
was inserted, in this case in the antecubital vein in the arm
opposite to the sampling arm, through which a glucose load
of 0.5 g/kg body weight was given as 50 percent dextrose.
Blood sampling was at 3, 5, 7, 10, 15, 20, 30, 45, 60, 75,
90, 120, 150, and 180 minutes following injection of glucose,
and there was no augmentation of accompanying insulin
concentrations.
2.4. Laboratory Measurements. Routine hematology inclu-
ded measurement of WBC. ESR was measured by the Wes-
tergren method. Routine biochemistry included measure-
ment of serum globulin and albumin concentrations. These
measurementsweremade using standard laboratorymethod-
ology in our own laboratories or local hospital chemical
pathology laboratories. Plasma glucose and insulin and
serum total, HDL cholesterol, and triglyceride concentrations
were measured in our own laboratories as described previ-
ously [17]. Quality control was monitored with commercially
available lyophilized sera and by participation in national
schemes. Between-batch assay coefficients of variation were
plasma glucose <3%; plasma insulin <6%; serum cholesterol
and triglycerides < 2%; serum HDL cholesterol <4%; serum
globulin and albumin concentrations <6%. Throughout the
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course of the HDDRISC study, changes in measurement
methodology were accompanied by detailed comparisons
between methods, with application of correction factors if
necessary to maintain continuity of measurement standard-
ization. On completion of data collection for the study,
detailed checks were also made to exclude the possibility of
laboratory drift significantly affecting results.
2.5. Data Analysis. BMI was calculated as the weight (kg)/
height (m)2. The mean of the three skinfold thickness mea-
surements was calculated, and percent body fat (SF %fat) was
calculated from the individual means for the four skinfold
thickness measures, according to the method of Durnin
and Womersley [13]. Body fat mass (SF total fat) was then
calculated as body weight × (SF %fat/100). The DXA-derived
measurement of total body fat mass (DXA total fat) was
expressed as a percentage of body weight (DXA %fat).
Proprietary software was used to distinguish upper body or
android fat (DXA android) and lower body or gynoid fat
(DXA gynoid) in the DXA scan. The region representative
of android fat was defined by an upper horizontal border
underneath the chin with vertical borders passing down
beside the ribs and a lower border formed by diagonal lines
passing through the hip joints and meeting at the perineum.
The region representative of gynoid fat was defined as the
tissue below these diagonal lines. Android or gynoid fat was
expressed as a percentage of DXA total fat (DXA % android
and DXA % gynoid, resp.). The CV for DXA fat was 1.8%,
while CVs for the regional measurements were all < 5% [18].
Current cigarette smoking was categorised as 0, <5, 5–
14, 15–24, and >24 cigarettes per day alcohol intake as 0,
<28, 28–56, and >56 units per week and exercise habit as
no regular, regular nonaerobic, and regular aerobic exe-
rcise. Serum low density lipoprotein (LDL) cholesterol con-
centration was calculated by the Friedewald method [19].
FPG and FPI were taken as the mean of the two fasting
measurements. The homeostasis model assessment index of
insulin resistance (HOMA-IR) derived from FPG and FPI
was calculated [20]. An OGTT-derived index of insulin
sensitivity was provided by the Matsuda index (Matsuda-
Si) [21]. An IVGTT-derived measure of insulin sensitivity,
Si, (IVGTT-Si) was provided by minimal model analysis
of IVGTT glucose and insulin concentrations, implemented
according to an optimised algorithm, as described previously
[16].
2.6. Statistical Analysis. All data was analysed using STATA
8 for Windows (Stata, College Station, TX, USA). Summary
measures were median and interquartile range for con-
tinuous variables and percentages for categorical variables.
For parametric analyses, measures were square root or log,
transformed as appropriate to normalize their distributions.
ANOVA for continuous variables and chi-square for categor-
ical variables were used to identify significant variation in
BMI and risk marker measures between the groups studied.
Dummy variables were assigned for each cigarette smoking,
alcohol intake, and exercise category. Relationships between
adiposity measures and between each adiposity measure and
each risk marker were explored by partial correlation, taking
into account covariation with age, cigarette smoking, alcohol
intake, and exercise habit. A significance level of 𝑃 < 0.05
was adopted with no correction for multiple testings, each
correlation undertaken being strongly weighted by existing
evidence, thus rendering the universal null hypothesis inap-
plicable [22]. These analyses were repeated with exclusion
of measurements lying >3SD outside the mean (theoretically
excluding 0.3% of the data) to minimise any leverage due to
outliers. The magnitude and differences in the strengths of
the relationships between measures of total body fat and risk
markers were explored by comparing confidence intervals
for regression coefficients derived from regression analyses
incorporating age, cigarette smoking, alcohol intake, and
exercise.
3. Results
Participant characteristics in each of the three groups are
summarised in Table 1. Ages ranged between 26 and 79 years
and BMI between 18.4 and 34.9 kg/m2. Of the 349 men in the
BMI/SF group, 65 percent were nonsmokers and 55 percent
had an alcohol intake less than 28U/wk, 1.2 percent were
taking blood pressure-lowering agents and 0.3 percent lipid-
lowering agents. There was significant variation between the
groups in age (𝑃 < 0.001), those in the BMI/SF group hav-
ing a median age of 47.2 years in contrast with 49.4 in the
BMI/DXA group and 54.2 in the BMI/SF/DXA group. There
was also significant variation in BMI (𝑃 < 0.001) although
median BMI in the three groups only varied between 25.1
and 25.5 Kg⋅m−2. Smoking (𝑃 < 0.001), alcohol intake (𝑃 <
0.001), and exercise (𝑃 < 0.01) also varied between the
groups, with heavier smoking, greater alcohol intake, and
more exercise evident in the BMI/SF group than in the BMI/
DXA or BMI/SF/DXA groups. Blood pressures (𝑃 < 0.05)
and serum triglyceride concentrations (𝑃 < 0.001) were hig-
her in the BMI/SF group, and, on the basis of higher levels of
ESR and globulin and lower albumin levels (𝑃 < 0.001), there
was evidence of greater inflammation in the BMI/SF group.
3.1. Relationships between Adiposity Measures. BMI was
strongly associated with SF total fat, SF %fat, DXA total
fat, and DXA %fat (partial correlations 0.68–0.84, 𝑃 <
0.001). BMI was also strongly associated with DXA android
and gynoid fat (partial correlations 0.68–0.81, 𝑃 < 0.001).
Somewhat weaker associations were seen between BMI and
individual skinfold thicknesses (partial correlations 0.37–
0.69, 𝑃 < 0.001), and the weakest associations were seen
between BMI and DXA % android and DXA % gynoid fat
(partial correlations 0.30 and −0.30, resp., 𝑃 < 0.001). DXA
% android and DXA % gynoid fat were inversely correlated
with an 𝑅 value of −0.91 (𝑃 < 0.001). Adiposity measures
lying outside 3SD from the mean from these analyses made
only very minor differences to the associations observed.
3.2. Relationships between Risk Factors and Adiposity Mea-
sures. Our three study groups represent three samples of
relationships between BMI and risk factors and two samples
of relationships between skinfold thickness-derived mea-
sures and DXA-derive measures and risk factors. Relative
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Table 1: Study group characteristics.
BMI/SF
𝑛 = 349
BMI/DXA
𝑛 = 269
BMI/SF/DXA
𝑛 = 156
ANOVA or chi
square
significance
Age (yr) 47.2 (41.6–52.1) 49.4 (42.8–57.0) 54.2 (43.1–60.6) <0.001
BMI (kg/m2) 25.2 (23.6–26.8) 25.5 (24.2–27.3) 25.1 (23.8–26.7) <0.001
Smoking (cigarettes per day %) <0.001
Nonsmoker 65 82 79
<5 20 9 10
5–14 3 6 6
15–24 6 3 4
>24 6 1 1
Alcohol (units/week %) <0.001
Never drinks 2 2 3
<28 55 75 73
28–56 units/week 33 21 21
>56 units/week 10 2 3
Exercise (%) <0.007
No exercise 39 43 49
Nonaerobic 47 42 42
Aerobic 14 15 9
Drugs (%)
Lipid lowering 0.3 1.9 2.6 0.05
Blood pressure lowering 1.2 6.0 7.7 0.001
SF fat (Kg) 19.6 (16.1–22.9) — 20.7 (17.3–25.0) —
DXA fat (Kg) — 19.6 (16.5–24.9) 18.5 (15.8–22.2) —
SF % fat 24.5 (20.9–27.3) — 25.8 (22.6–29.4) —
DXA % fat — 24.2 (21.4–28.8) 23.3 (20.3–26.6) —
SF triceps (mm) 10.9 (8.5–13.4) — 10.5 (8.9–12.8) —
SF biceps (mm) 6.1 (4.9–8.0) — 6.1 (5.0–7.8) —
SF subscapular (mm) 16.9 (13.3–20.0) — 16.6 (13.6–21.3) —
SF iliac (mm) 15.0 (10.7–20.0) — 18.7 (13.5–24.4) —
DXA android (Kg) — 10.6 (8.4–13.8) 9.5 (7.8–12.0) —
DXA gynoid (Kg) — 6.1 (5.2–7.5) 6.0 (5.2–7.2) —
DXA % android (%) — 54.0 (50.1–57.5) 51.5 (47.4–55.0) —
DXA % gynoid (%) — 31.9 (28.6–35.0) 33.2 (30.9–36.0) —
Systolic BP (mmHg) 125 (115–135) 120 (110–135) 120 (110–140) 0.6
Diastolic BP (mmHg) 80 (70–90) 80 (70–85) 80 (70–85) 0.01
Cholesterol (mmol/L) 5.5 (4.8–6.3) 5.3 (4.8–6.0) 5.2 (4.7–5.8) 0.01
LDL cholesterol (mmol/L) 3.6 (2.9–4.2) 3.4 (2.9–4.0) 3.3 (2.9–3.9) 0.1
Triglycerides (mmol/L) 1.23 (0.93–1.70) 1.16 (0.82–1.76) 1.06 (0.72–1.51) <0.001
HDL cholesterol (mmol/L) 1.30 (1.12–1.51) 1.25 (1.08–1.46) 1.27 (1.07–1.48) 0.07
FPG (mmol/L) 5.3 (5.0–5.6) 5.3 (5.0–5.6) 5.3 (5.1–5.6) 0.02
FPI (mU/L) 10.5 (6.0–15.5) 9.5 (6.5–13.6) 10.0 (7.0–14.3) 0.1
HOMA-IR 2.4 (1.5–3.8) 2.3 (1.5–3.3) 2.4 (1.6–3.4) 0.1
Matsuda-Si 4.6 (3.0–6.9) — — —
IVGTT-Si (/min/mU/L) — 3.2 (2.3–4.5) 3.2 (2.3–4.4) —
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Table 1: Continued.
BMI/SF
𝑛 = 349
BMI/DXA
𝑛 = 269
BMI/SF/DXA
𝑛 = 156
ANOVA or chi
square
significance
WBC (109/L) 5.5 (4.7–6.5) 5.3 (4.5–6.2) 5.2 (4.5–6.2) 0.1
ESR (min) 5 (2–10) 3 (2–6) 3 (2–7) <0.001
Globulin (g/L) 24 (22–27) 22 (20–24) 22 (20–24) <0.001
Albumin (g/L) 42 (40–44) 45 (43–47) 44 (43–46) <0.001
Medians (interquartile ranges) for continuous variables and group percentages for categorical variables are shown.
BMI: body mass index; SF: skinfold thickness; DXA: dual energy X-ray absorptiometry; BP: blood pressure; LDL: low density lipoprotein; HDL: high density
lipoprotein; FPG: fasting plasma glucose; FPI: fasting plasma insulin; IVGTT-Si: intravenous glucose tolerance test insulin sensitivity; HOMA-IR: homeostasis
model assessment of insulin resistance; WBC: white blood cell count; ESR: erythrocyte sedimentation rate.
Table 2: BMI/SF (𝑛 = 349). Partial correlation coefficients and significances between risk marker and body fat measures, independent of age,
smoking, alcohol intake, and exercise habit.
BMI SF fat SF triceps SF biceps SF sub-scapular SF iliac
Systolic BP 0.05 0.09 0.10 0.06 0.12∗ 0.10
Diastolic BP 0.13# 0.14∗ 0.13∗ 0.15# 0.18# 0.19§
Triglyceride 0.24§ 0.20# −0.14∗ 0.24§ 0.21§ 0.17#
HDL Cholesterol −0.15# −0. 12∗ −0.10 −0.11 −0.16# −0.05
FPG 0.17# 0.06 0.02 0.09 0.08 0.05
FPI 0.18# 0.19# 0.10 0.14∗ 0.14∗ 0.13∗
HOMA-IR 0.20# 0.19# 0.10 0.15# 0.15# 0.13∗
Matsuda-Si −0.33§ −0.29§ −0.14# −0.25§ −0.24§ −0.20§
ESR 0.11∗ 0.07 0.05 0.10 0.07 0.05
Significances: ∗𝑃 < 0.05; #𝑃 < 0.01; §𝑃 < 0.001.
DXA: dual-energy X-ray absorptiometry; SF: skinfold thickness.
strengths of association according to each adiposity measure
are only considered for those risk factors for which each
sample showed a significant relationship. Associations for
SF and DXA percent fat and risk factors did not differ
from those for SF total and DXA total fat and risk factors.
Associations between adiposity measures and total and LDL
cholesterol, WBC, globulin, and albumin only exhibited
isolated significances that were inconsistent between samples.
These associations are not considered further. Measures
lying outside 3SD from the mean from these analyses made
only very minor differences to the associations observed.
Associations in the BMI/SF/DXA group, independent of
age, cigarette smoking, alcohol intake, and exercise habit,
between adiposity measures and the key risk factors for
which the strongest associations were apparent, IVGTT-Si,
triglycerides, and systolic BP, are illustrated by standardised
regression coefficients in Figure 1.
3.3. Blood Pressure. Associations between systolic and dias-
tolic BP and BMI and skinfolds in the BMI/SF group were
relatively weak (𝑅 < 0.20), the most consistent associations
being seen for diastolic BP, with little differences in stre-
ngth of association between the different adiposity measures
(Table 2). Stronger associations were apparent in the BMI/
DXA group (𝑅 = 0.31, 𝑃 < 0.001 for BMI with both systolic
and diastolic BP: Table 3) and in the BMI/SF/DXA group
(𝑅 = 0.34 and 0.29, 𝑃 < 0.001 for systolic and diastolic BP,
resp., Table 4). The strongest associations between blood
pressure and adiposity measures were seen with BMI.
3.4. Lipids and Lipoproteins. In each of the three groups stud-
ied, significant associations were apparent between triglyc-
eride concentrations and all measures of adiposity except tri-
ceps skinfold and DXA gynoid fat in the BMI/SF/DXA group
(Tables 2–4).The strongest associations between triglycerides
and adiposity measures were seen with BMI (BMI/SF group,
𝑅 = 0.24; BMI/DXA group, 𝑅 = 0.41; BMI/SF/DXA group,
𝑅 = 0.34, all 𝑃 < 0.001). Similar associations were apparent
betweenHDL cholesterol and adipositymeasures, but weaker
and in the opposite direction.
3.5. Insulin Sensitivity-Related Measures. In the BMI/SF
group, significant negative associations were apparent bet-
ween Matsuda Si and all measures of adiposity, with the
strongest association being seen with BMI (𝑅 = −0.33, 𝑃 <
0.001, Table 2). Similar associations were apparent between
HOMA-IR, FPI, and adiposity measures, but weaker and in
the opposite direction. In the BMI/DXA group significant
negative associations were apparent between IVGTT-Si and
all measures of adiposity, with the strongest association being
seen with DXA android fat (𝑅 = −0.47, 𝑃 < 0.001, Table 3).
Strong associations were also seen with BMI and DXA total
fat (𝑅 = −0.42 and −0.46, resp., 𝑃 < 0.001). Similar asso-
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Figure 1: BMI/SF/DXA (𝑛 = 156). Variation in insulin sensitivity,
triglycerides, and systolic blood pressure with body fat measures.
Regression coefficients (±95% confidence interval) for prediction
of (a) insulin sensitivity, IVGTT-Si; (b) serum triglyceride con-
centration; and (c) systolic blood pressure by BMI (open bars),
skinfold thicknesses (closed bars), and DXA measures (hatched
bars) recorded at the same visit. Standardised data was used;
therefore, bars show the number of standard deviations change
in IVGTT-Si, triglycerides, and systolic BP for a 1SD change in
each body fat measure. Age, cigarette smoking, alcohol intake, and
exercise habits were included in the prediction models.
ciations were apparent between HOMA-IR, FPI, and adipos-
ity measures, but weaker and in the opposite direction, and
associations similar to those in the BMI/DXA group were
seen in the BMI/SF/DXA group.
3.6. Inflammation-Related Measures. The only consistent
associations between inflammation-related measures and
measures of adiposity were between ESR and DXA total and
android fat (𝑅 = 0.16–0.19, 𝑃 < 0.05, Tables 3 and 4).
3.7. Effects of Regional Adiposity Independent of Total Adipos-
ity. To explore whether there was any contribution of regi-
onal body fat to risk marker variation independent of vari-
ation in total fat, each skinfold or DXA measure of regi-
onal fat was paired with its correspondingmeasure of total fat
in partial correlation analysis. This analysis was restricted to
the BMI/SF/DXA group, in which the strongest associations
were seen between adiposity measures and risk markers.
Associations between risk markers and SF total fat were
relatively unaffected by pairing with triceps, biceps, and
supra-iliac skinfold measures, each of which showed few
significant associations when paired with SF total fat. There
was, however, evidence of an independent contribution of the
subscapular skinfold to variation triglycerides and colinearity
between SF total fat and subscapular skinfold with respect
to IVGTT-Si (results not shown). With inclusion of DXA
android fat with DXA total fat (Table 5), both DXA total fat
and DXA android fat ceased to be significantly associated
with SBP, HDL cholesterol, and FPG, suggesting strong colin-
earity betweenDXA total fat andDXAandroid fat.Therewas,
however, evidence of an independent effect of DXA android
fat on measures of insulin sensitivity. With inclusion of DXA
gynoid fat with DXA total fat (Table 5), both DXA total fat
and DXA gynoid fat remained associated with variation in
serum triglycerides and insulin sensitivity-related measures,
but the direction of association with DXA gynoid fat was
reversed, rendering its associations similar to those seen with
DXA % gynoid fat. DXA android and gynoid fat were also
entered in a paired analysis of riskmarker variation (Table 5).
In this analysis, DXA android fat remained significantly
associated with a range of risk markers, particularly serum
triglycerides and insulin sensitivity-related measures, but
associations between DXA gynoid fat and risk markers were
eliminated for all risk markers except DBP, triglycerides, and
albumin.
4. Discussion
Our findings confirm our hypothesis that, in this group of
adult males, BMI, a simple measure of overall adiposity, can
account for variation in a broad range of adiposity-related
risk markers as effectively as more sophisticated measures
derived from skinfold or DXA measurements. To the best
of our knowledge, this is the first study to compare in a
single investigation BMI, skinfolds, and DXA as correlates of
risk marker variation in white adult males. One other study,
that is of Steinberger and colleagues [23], combined BMI,
skinfold, and DXA adiposity measures, but in 72 adolescent
males and 58 adolescent females of white or black race and
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Table 3: BMI/DXA (𝑛 = 269). Partial correlation coefficients and significances between risk marker and body fat measures, independent of
age, smoking, alcohol intake, and exercise habit.
BMI DXA fat DXA android DXA gynoid DXA % android DXA % gynoid
Systolic BP 0.31§ 0.22∗ 0.22§ 0.15∗ 0.11 −0.12∗
Diastolic BP 0.31§ 0.27§ 0.25§ 0.26# 0.03 −0.04
Triglyceride 0.41§ 0.34§ 0.40§ 0.17# 0.36§ −0.37§
HDL Cholesterol −0.31§ −0.25§ −0.27§ −0.17# −0.18# 0.20#
FPG 0.16∗ 0.13∗ 0.12 0.10 0.05 −0.10
FPI 0.30§ 0.33§ 0.32§ 0.28§ 0.12∗ −0.16∗
HOMA-IR 0.31§ 0.33§ 0.32§ 0.28§ 0.12∗ −0.16#
IVGTT-Si −0.42§ −0.46§ −0.47§ −0.33§ −0.27§ 0.30§
ESR 0.12 0.16∗ 0.16∗ 0.12 0.05 −0.07
Significances: ∗𝑃 < 0.05; #𝑃 < 0.01; §𝑃 < 0.001.
DXA: dual-energy X-ray absorptiometry; SF: skinfold thickness.
with insulin sensitivity being measured by the euglycaemic
hyperinsulinaemic clamp. Despite these differences, their
conclusions agree with our finding that BMI is as effective
at accounting for risk marker variation as skinfold or DXA-
derived measures.
Other studies, that have included DXA but not skinfold
thickness measurements, have reported little difference in
strength of association between simple anthropometric and
DXA measures of adiposity with respect to risk marker
variation [24–28], and there is also evidence that this is
the case with regard to studies including BMI and skinfold
but not DXA measurements [29, 30]. Moreover, there is
even evidence that risk marker associations with simple,
anthropometric measures of adiposity can be comparable
to those with specific fat depots quantified by magnetic
resonance imaging (MRI) [31].
Nevertheless, a number of other studies in which spe-
cific fat depots have been measured by MRI or computed
tomography have raised the possibility that the visceral fat
depot, with its circulation draining into the hepatic portal
vein, is particularly associated with risk marker variation
[32–34]. It has been proposed that variation specifically
in the visceral fat depot can account for discrepancies in
associations between risk markers and overall adiposity,
with some obese individuals being metabolically healthy and
some individuals with apparently normal levels of adiposity
exhibiting a metabolic phenotype typical of obesity [35].
However, a number of other studies have found risk marker
variation to be equally associated with variation in visceral
or subcutaneous fat depots [36–40]. The relative importance
of the visceral and subcutaneous fat depots in risk marker
variation could vary according to age, race, or gender and
may be affected by variation in the strengths of relationship
according to degree of overweight, with the visceral fat depot
assuming more importance in overt obesity [41, 42].
Our study has limitations and strengths. Recruitment
was in the context of a long-running, open cohort study
and the participants and the periods during which data was
being collected differed between the three groups studied.
Consequently, results were based on three cross-sectional
samples, which differed in demographic and risk factor
characteristics. Findings should, therefore, be interpreted
with caution. It should be noted, however, that relative
strengths of association between measures of adiposity
and risk factors were generally comparable between cross-
sections, which lends support to their validity.
A further potential limitation of our study was that waist
and hip circumferences were not measured. Various anth-
ropometric measures of centrally concentrated adiposity,
including waist circumference, waist hip ratio, and waist
height ratio, have been explored in previous studies in
relation to clinical outcomes and have generally been found
to predict clinical outcomes more strongly than BMI [9, 43],
although the differential in improvement may be small [8,
44]. It is questionable, however, whether anthropometric
measures of centrality would have provided any more infor-
mation than that provided by the DXA measurements of
android fat included in our study. Nevertheless, given that
central fat measures are more predictive of clinical outcomes
and that the central fat measure in our study showed little
difference from BMI in the strengths of its relationships
with the risk factors we measured, it may be inferred that
there are factors associated with variation in central fat that
we did not measure but which impact strongly on clinical
outcomes [45, 46]. A particular advantage of our analysis
was the relatively low use of medications likely to affect risk
marker variation, particularly use of lipid-lowering agents,
the majority of measurements having been carried out before
the inception of the current, widespread use of these agents.
A further advantage was the broad range of risk markers
available for analysis, which allowed for strong confirmation
of the relative strengths of association between risk markers
and adiposity measures.
The three indices of total body fat, BMI, SF total fat, and
DXA total fat were closely correlated, as was subscapular
skinfold with SF total fat and DXA android and gynoid
with DXA total fat. Risk marker associations suggested
that subscapular skinfold alone might predict risk marker
variation as effectively as a measure of total adiposity derived
from all four skinfolds. As mentioned, DXA android fat
conveyed as much if not more information in this respect
as did DXA total fat and risk marker associations with DXA
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Table 5: Partial correlation coefficients between risk marker measures and paired DXA measures (𝑛 = 156). Three correlation analyses
were explored: Analysis 1: risk factor versus DXA total, DXA android, age, smoking, alcohol intake and exercise habit.Analysis 2: risk factor
versus DXA total, DXA gynoid, age, smoking, alcohol intake and exercise habit.Analysis 3: risk factor versus DXA android, DXA gynoid, age,
smoking, alcohol intake and exercise habit.
Analysis 1 Analysis 2 Analysis 3
DXA total DXA android DXA total DXA gynoid DXA android DXA gynoid
Systolic BP 0.08 −0.02 0.06 0.02 0.06 0.07
Diastolic BP 0.17∗ −0.12 −0.03 0.14 −0.03 0.19∗
Total Cholesterol −0.06 0.07 0.10 −0.11 0.08 −0.09
LDL Cholesterol 0.00 0.00 0.02 −0.02 0.01 −0.01
Triglyceride −0.16 0.23# 0.32§ −0.26# 0.32§ −0.19∗
HDL Cholesterol 0.03 −0.10 −0.18∗ 0.09 −0.19∗ 0.03
FPG 0.00 0.08 0.24# −0.13 0.23# −0.04
FPI −0.06 0.19∗ 0.34§ −0.18∗ 0.35§ −0.07
HOMA-IR −0.05 0.19∗ 0.36§ −0.19∗ 0.36§ −0.07
IVGTT-Si 0.08 −0.22# −0.37§ 0.22# −0.38§ 0.10
white cell count 0.04 −0.02 0.12 −0.10 0.07 −0.04
ESR 0.00 0.06 0.21∗ −0.14 0.18∗ −0.06
globulin 0.01 −0.03 −0.07 0.05 −0.06 0.02
albumin −0.13 0.16 0.22# −0.20∗ 0.21∗ −0.17∗
Significances: ∗𝑃 < 0.05; #𝑃 < 0.01; §𝑃 < 0.001.
DXA: dual-energy X-ray absorptiometry; SF: skinfold thickness.
% android followed closely on those with DXA android fat.
However, the pattern of associationswithDXAgynoid fat was
markedly different in that DXA%gynoid fat showed opposite
directions of association with risk markers to those seen
with DXA gynoid fat mass. The strong positive association
between DXA gynoid and DXA total fat masses suggests that
the DXA gynoid measure incorporates a strong component
of variation that simply reflects net adiposity and this could
account for the unfavourable associations seen between risk
markers and DXA gynoid fat. Rendering DXA gynoid as a
percentage of body fat, however, distinguished variation in
gynoid fat fromvariation in total fat. As a result ofmaking this
distinction, it was apparent that there may be a component of
variation in gynoid or lower body fat that has a favourable
effect on risk marker variation, as has been suggested by
previous studies [47–51]. However, DXA % gynoid fat was
also strongly, inversely, associated with DXA % android fat,
and it could be argued that a high percentage of gynoid
fat merely reflects a low percentage of android fat (and vice
versa); the favourable associations seen between risk markers
and DXA% gynoid are thenmerely secondary to variation in
android fat. The analyses we present in Table 5, in which risk
marker associations with DXA gynoid fat largely disappeared
with inclusion of DXA android fat, which supports the
possibility that the favourable associations seen between
risk markers and DXA % gynoid are merely secondary to
variation in android fat. If DXA gynoid fat had been having
an underlying, independent, favourable effect on risk marker
variation, these favourable associations would have been
expected to remain despite inclusion of android fat in the
analysis.
Overall, the strongest associations seen with variation
in any measure of adiposity were with measures of insulin
sensitivity, followed by serum triglyceride, HDL cholesterol
concentrations, and then blood pressure. Serum cholesterol
and LDL cholesterol concentrations varied inconsistently
with adiposity [52, 53]. Consistent relationships between
adiposity and indices of inflammation were restricted to
positive associations between DXA total and android fat
and ESR. In contrast to our findings, significant associations
between white cell count and BMI have been reported [54],
but their magnitude can be relatively small [55]. Adiposity-
related inflammation relates to macrophage infiltration and
activation and is associated with elevated levels of specific
cytokines including interleukin-6, tumour necrosis factor-
alpha, and acute phase proteins such as C-reactive protein
[6]. It is possible that, had we measured these, stronger
associations would have been apparent. It is, nevertheless,
noteworthy that in this cohort the inflammation markers
we evaluated are significantly related to clinical outcomes
[56, 57].
In conclusion, BMI can account for variation in risk
markers in white, predominantly middle-aged males as well
as more sophisticated measures derived from skinfold thick-
ness measurements or DXA scanning.
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